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Abstract
The rise of antibiotic resistance is a growing public health crisis. Novel antimicrobials are sought, 
preferably developing nontraditional chemical scaffolds that do not inhibit standard targets such as 
cell wall synthesis or the ribosome. Iron scavenging has been proposed as a viable target, because 
bacterial and fungal pathogens must overcome the nutritional immunity of the host to be virulent. 
This review highlights the recent work toward exploiting the biosynthetic enzymes of siderophore 
production for the design of next generation antimicrobials.
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1. Introduction
Antibiotic resistance is of major concern, and novel therapies are in urgent need to combat 
this growing health crisis. In response to the United States Presidential Executive Order to 
combat antibiotic resistant bacteria [1], the Centers for Disease Control and Prevention have 
announced the Antibiotic Resistance Solutions Initiative [2]. The World Health Organization 
is drafting a Global Action Plan on antimicrobial resistance [3]. These national and 
international proposals include plans for promoting awareness and education of the problem, 
directives for improved antibiotic stewardship, goals for prevention and response to 
outbreaks, and investment in the design of new antibiotics and diagnostics.
One viable mechanism for the development of novel antimicrobial agents is targeting 
bacterial pathways responsible for acquisition of essential nutrients [4]. Indeed, our defense 
systems against bacterial pathogens include “nutritional immunity” – withholding of 
nutrients [5]. Iron serves as an important cofactor for a variety of enzymes that perform 
crucial reactions, including roles in electron transfer, resistance to reactive oxygen 
intermediates, and RNA synthesis. Fe(III) is very insoluble and biologically inaccessible 
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such that the concentration of free ferric iron available to pathogens in the human host 
ranges in estimation from 10−15 to 10−24 M [6, 7], whereas a typical pathogenic bacterium 
requires ~1 μM iron for optimal growth [7]. In response, bacterial pathogens have developed 
a variety of systems to scavenge iron from the host, including methods to import 
hemoproteins and other iron binding proteins such as transferrin, and the use of hemophores, 
heme-scavenging molecules [5]. The focus of this review is the biosynthesis of low 
molecular weight iron chelators called siderophores. Bacteria synthesize, secrete, and then 
selectively take up the iron-loaded siderophore to colonize human tissues [8–10]. 
Siderophore biosynthetic enzymes frequently have no human homologues, making them 
attractive antimicrobial targets [11].
2. Siderophore biosynthesis
Compounds from primary metabolism serve as a source of building blocks to generate 
siderophore natural products with differing levels of complexity both chemically and 
biologically. Diagrams of the siderophores are included as they appear in the discussion, 
detailing their chemical simplicity (ex. pyochelin) or complexity (ex. pyoverdin). 
Siderophores sometimes have roles not only in iron chelation, but can also have roles in 
other biological processes such as quorum sensing. To start our discussion, an overview of 
the biosynthetic process is provided. Bacterial pathogens synthesize siderophores using 
nonribosomal peptide synthetase (NRPS) enzymes, polyketide synthase (PKS) enzymes, 
and/or by NRPS independent siderophore (NIS) synthetase enzymes.
2.1. Nonribosomal peptide synthetase (NRPS) biosynthesis
Siderophores generated by NRPS enzymes are primarily composed of amino acids, 
including nonproteinogenic amino acids, linked by peptide bonds. Significant work in the 
field has detailed the mechanisms for peptide bond formation in NRPS enzymes, which are 
multidomain, multifunction assembly line enzymes (for excellent reviews, see [12, 13]). In 
short, a module consists of a condensation domain, an adenylation domain and a carrier 
domain (except for the first, which lacks a condensation domain). The amino acid is 
activated by conversion to an amino acyl-AMP by the adenylation domain and then 
covalently attached (with the loss of the AMP) to the carrier domain, priming the module 
(Figure 1A, top). The carrier domain can accept the amino acid because it was previously 
post-translationally modified by the addition of a phosphopantetheinyl moiety on a 
conserved serine (Figure 1C). When two adjacent modules are primed, the condensation 
domain forms a peptide bond between the two amino acids, leaving the dipeptide on the 
second carrier domain (Figure 1A, bottom). When the third carrier domain is primed, a 
second peptide bond is formed, generating a tripeptide on the third carrier domain. This 
assembly line mechanism continues until the chain is complete. A thioesterase domain, 
frequently in the final module, removes the complete chain from the final carrier domain. 
The secondary metabolites generated by NRPS systems are not merely short chain peptides. 
To generate the bioactive properties that make them useful, the peptides must be tailored. 
There are tailoring domains, both incorporated into the NRPS modules and stand-alone, that 
decorate or modify the amino acids of the chain. These modifications can be epimerization, 
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methylation, oxidation, reduction, hydroxylation, lipidation and glycosylation, among 
others.
2.2. Polyketide synthase (PKS) biosynthesis
Some siderophores are constructed from assembly line systems that include polyketide 
synthase (PKS) modules to include other functionalities into the backbone. A PKS module 
consists of a ketosynthase domain, an acyltransferase domain and a carrier domain (the 
loading module lacks a ketosynthase domain). An initiation unit (in Figure 1B, top, the 
example is propionyl-CoA) is covalently attached to the carrier domain by the 
acyltransferase domain with the loss of the CoA. An elongation unit (malonyl-CoA shown 
here) is similarly attached in module 1. In both cases, the modules are prepared to receive 
the chain because of the same phosphopantetheinyl post-translational modification noted in 
the NRSP system (Figure 1C). The acyl chain is transferred from the carrier domain of the 
loading module to a cysteine in the ketosynthase domain, priming module 1 (Figure 1B, 
bottom). The ketosynthase domain catalyzes the condensation reaction and the growing 
chain is now attached to the carrier domain of the first module, ready to translocate to the 
ketosynthase domain of the next module. The assembly line process continues, with 
differing tailoring domains incorporated into each module to allow for the addition of 
differing functionalities. Tailoring chemistries include but are not limited to ketoreductases, 
dehydratases, methyltransferases, and oxidases. A thioesterase domain removes the 
complete chain from the final carrier domain, by reduction, hydrolysis or sometimes 
cyclization. For excellent reviews see references [14, 15]. The carrier domains in both PKS 
and NRPS proteins allow for an easy transition between incorporation of ketides and amino 
acids into the backbones of siderophore chains.
2.3. NRPS-independent siderophore (NIS) synthetase biosynthesis
Some siderophores are not built in the assembly line fashion using NRSP or PKS modules. 
Instead, precursors are prepared and linked using NRPS-independent siderophore (NIS) 
synthetases [16]. The synthetases of these biosynthetic clusters generate siderophores that 
incorporate citric acid, α-ketoglutarate, and succinic acid. The NIS synthetase serves as an 
acyl adenylation domain (for example, generating a citryladenylate [citrate-AMP]) to 
provide an energy rich bond for a condensation reaction with an amino acid or polyamine. 
There is at least one known example of a siderophore generated by a combination of NIS 
and NRPS proteins [17].
3. Inhibitors under iron-limiting conditions
Inhibitors of siderophore biosynthesis may be identified by screening for compounds that 
prevent bacterial growth in iron-limiting media. This is especially true for pathogens that are 
dependent on a single siderophore for iron scavenging, or on a limited number of iron 
acquisition routes. One may hypothesize that pathogens that have developed and/or acquired 
several iron acquisition pathways may be less susceptible to drugs developed against a 
single system. However, the interplay between siderophore biosynthesis and other virulence 
mechanisms is complex, including the interplay of the regulation for production of different 
siderophores in the same organism [18]. As seen for several inhibitors in the coming 
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sections, inhibition of a single pathway can cause growth inhibition even for pathogens with 
seemingly redundant iron scavenging systems.
3.1. A generic screen for siderophore biosynthetic inhibitors
A screen has been described that was designed to identify inhibitors of siderophore 
biosynthesis by finding compounds that inhibit pathogen growth depending on the iron 
content of the media. Aspergillus fumigatus, a fungus that is the causative agent of invasive 
aspergillosis, was the model organism used. The screen requires two steps [19]. In the first 
step, A. fumigatus is grown in iron-poor or iron-replete media. Compounds that slow growth 
in iron-poor media but allow growth in iron-replete media carry forward to the second step. 
The fungi are grown again in iron-poor media with the compounds identified in the first 
step, and those that show no production of siderophores are to be considered hits. After this 
second growth, the cultures are filtered, and siderophore production is monitored as a color 
change upon the addition of iron since the Fe(III)-siderophore complexes are red. The 
method is described, but the results of a screen are not reported.
3.2. Siderophore mimics as inhibitors
Another screen aimed at growth inhibition under iron-limiting environments was based on 
the premise that compounds that resemble the structure of the siderophore may make good 
inhibitors of siderophore production, and focused on the pathogens Mycobacterium 
tuberculosis (causative agent of tuberculosis; siderophore: mycobactin) and Yersinia pestis 
(causative agent of plague; siderophore: yersiniabactin) [20]. As can be seen in Figures 2A 
and 2B, these siderophores share a common hydroxyphenyl-oxazoline/thiazoline scaffold 
which was the basis of the mimicking potential inhibitor library (scaffold shown in Figure 
2C). In this case, growth inhibitory concentrations were determined against M. tuberculosis 
and Y. pestis, with much better results for the latter organism showing high nanomolar EC50 
values1 and low micromolar MIC90 values2. Compounds were labelled as bacteriostatic 
(impairing the siderophore system and effective only in iron-limiting conditions), 
bactericidal (inhibiting other functions that are essential in iron-limiting conditions), and 
antimicrobial (inhibiting regardless of iron concentration), with all three categories 
identified by the chemically similar molecules from this screen.
A separate high throughput screen was built on the idea of seeking inhibitors in iron limited 
media, but not necessarily seeking inhibitors of siderophore production. The assay 
monitored growth inhibition of E. coli in the presence of the iron chelator 
ethylenediaminetetraacetic acid (EDTA) [21]. Compounds that allowed growth in the 
absence of EDTA were further considered, and compounds that took advantage of the 
membrane-compromising properties of EDTA were eliminated. Finally, the successful 
compounds were again screened in minimal media treated with chelex-resin to removed 
iron. A screen of 30,000 compounds identified three compounds that met all criteria. The 
best compound (low micromolar MIC90 value) was a spiro-indoline-thiadiazole (Figure 2D), 
which showed intracellular antibacterial activity. Intriguingly, the compound appears to be a 
1An EC50 value reports the half maximal effective concentration for inhibiting bacterial growth.
2An MIC90 value reports the minimum inhibitory concentration for inhibiting 90% of bacterial growth.
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siderophore mimic: in the presence of iron, the compound converts to a merocyanine metal 
chelator and was hypothesized to interrupt iron homeostasis.
3.3. Repurposing known drugs to target siderophore biosynthesis
Pseudomonas aeruginosa causes nosocomial infections in immune deficient patients, 
including chemotherapy patients and burn patients, and causes chronic lung infections in 
cystic fibrosis patients. P. aeruginosa produces two siderophores under iron-limiting 
conditions: pyochelin and pyoverdin (Figure 3). Using a commercial library of bioactive 
compounds, a screen was developed to find inhibitors of pyoverdin production by finding 
compounds that prevent the expression of the iron-starvation alternate signaling factor PvdS 
[22]. PvdS promotes the expression of the exoprotease and exotoxin A virulence factors, and 
the expression of the pyoverdin biosynthesis genes when iron is limiting. The compound 
flucytosine (Figure 3C), an antimycotic fluorinated pyrimidine, was found to be effective in 
preventing pvdS gene expression, thereby causing a down-regulation of virulence genes 
including the pyoverdin biosynthetic genes, and was found to be effective in reducing P. 
aeruginosa pathogenicity in a mouse model.
4. Inhibitors of NRPS biosynthesis
Inhibitors of the catalytic activities of NRPS domains have focused on two activities: the 
production of the thiol tether on the carrier domain and the activation of the amino acids by 
adenylation. The logic of the researchers for choosing these proteins is likely two-fold: a 
desire for broadly applicable drugs and the ease or cost of the experiment. All of the 
assembly lines require the phosphopantetheinyl post-translational modification, and the 
enzymes that catalyze the reaction have been shown to be promiscuous across assembly 
lines and species [23]. Indeed, Sfp was originally cloned from Bacillus subtilis (a model 
organism) [24], and is commonly used in the laboratory to add the phosphopantetheinyl 
group to carrier domains from a wide variety of assembly lines. Therefore, compounds 
developed against Sfp and its homologues may be applicable to a wide array of pathogens 
that utilize NRPS and PKS dependent virulence factors. In contrast, adenylation domains are 
not promiscuous; indeed, the amino acid sequence of the peptide backbone made by NRPS 
enzymes has been hypothesized to be largely the result of adenylation domain substrate 
specificity [25]. Nevertheless, inhibitors designed to block the activation of amino and 
hydroxy acids by the adenylation domains are potentially also broadly applicable, because 
many chains contain common building blocks (for example, the salicylate and 
dihydroxybenzoate caps noted later in this section). Finally, most NRPS protein targets are 
multidomain, multifunctional polypeptides that contain at least one module and are quite 
large, ~120 kDa for an adenylation, carrier and condensation domain. In contrast, Sfp is a 
two domain protein of ~26 kDa and the adenylation domains exploited in drug design are 
stand-alone domains of ~60 kDa, making assay development easier and more economical.
4.1. Phosphopantetheinyl transferase inhibitors
The carrier domains must be post-translationally modified to be ready to accept the building 
blocks of NRPS and PKS siderophore biosynthesis. The phosphopantetheine moiety of CoA 
is attached to a serine residue producing a “swinging arm” [26] (Figure 1C). The amino 
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acids (NRPS biosynthesis) or ketides (PKS) are covalently attached through the thiol, 
providing an anchor for chain extension and tailoring reactions. This linkage is denoted as a 
wavy line in Figure 1. The Sfp-type phosphopantetheinyl transferases (PPTases) are 
responsible for modifying the carrier domains of NRPS and PKS enzymes (as opposed to 
the AcpS-PPTases for fatty acid biosynthesis), and have been targeted for inhibition. A 
traditional assay for determining activity in PPTase enzymes is to measure radiolabel 
incorporation from the addition of tritiated-CoA to a carrier domain. This assay has been 
miniaturized for high throughput screening with the development of a scintillation proximity 
assay for M. tuberculosis PPTase [27]. The radiolabelled carrier domain, when in proximity 
of the scintillation beads, causes the emission of light. Inhibitors of the PPTase prevent the 
transfer of the radiolabel to the carrier domain, thereby eliminating the scintillation signal.
A high throughput assay dependent on fluorescence resonance energy transfer (FRET) for 
the Sfp-PPTase from B. subtilis has been developed (Figure 4A) [28, 29]. The FRET 
acceptor (a TAMRA-labeled CoA) is covalently attached by the PPTase enzyme to the 
serine residue (red) in the FITC-labeled peptide [30], a FRET donor. When the two are 
linked by the PPTase enzyme, FRET occurs. Inhibitors of the PPTase enzyme will prevent 
the attachment of the TAMRA-CoA to the peptide, preventing the FRET signal [28, 29]. A 
subsequent high throughput screen of over 300,000 compounds yielded the identification of 
ML267 (Figure 4B) as an inhibitor of Sfp-PPTase, with approximately 30-fold selectivity 
over the bacterial fatty acid synthesis PPTase and greater than 500-fold relative to the 
human orthologue [31, 32]. ML267 is an allosteric, reversible inhibitor with a high 
nanomolar IC50 value 3 that is bactericidal against Gram positive pathogens including B. 
subtilis and methicillin-sensitive and -resistant strains of Staphylococcus aureus (MRSA).
Two fluorescence polarization assays have also been described for the detection of inhibitors 
of PPTase enzymes [33, 34]. In the first example, a BODIPY-TMR-labeled CoA serves as a 
fluorescence polarization probe (Figure 4C). The fluorescent CoA produces a polarized 
signal when bound to the Sfp enzyme (tumbling in solution is slow because the probe is 
bound to the PPTase). Inhibitors displace the probe from the PPTase active site leading to a 
decrease in fluorescence polarization (the tumbling rate is increased because probe is no 
longer bound to protein) [33]. In a second fluorescence polarization assay, the probe used is 
the TAMRA-labeled FRET acceptor in Figure 4A. The TAMRA-CoA is attached to a 
carrier domain by a PPTase, causing an increase in fluorescence polarization (the tumbling 
rate is slowed, because probe becomes bound to protein) [34]. A limited screen was 
performed using the PPTase from M. tuberculosis to label a carrier domain of VibB for 
vibriobactin biosynthesis (Vibrio cholera, causative agent of cholera) or a carrier domain of 
mycocerosic acid synthase from M. tuberculosis [35]. The most effective inhibitors were 
calmidazolium and sanguinarine with low micromolar IC50 values (Figure 4D). 
Sanguinarine will appear again as an inhibitor of the ornithine hydroxylase, identified using 
a remarkably similar fluorescent probe, despite a lack of similarity in the target enzyme 
structure or function (Section 7.3).
3An IC50 value reports the half maximal enzyme inhibitory concentration.
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4.2. Adenylation domain inhibitors
4.2.1 Salicylate adenylation inhibitors—The first step in the NRPS assembly line is 
the priming of carrier domains with the initiator or elongation units. This is accomplished by 
the adenylation domains (Figure 1), which can be embedded in the NRPS, or can be stand-
alone domains. For ease in inhibitor design, the stand-alone domains have been 
predominantly used, because the multidomain NRPS modules are large and can be difficult 
to express and purify, especially in sufficient quality and quantity. The adenylation domains 
that activate the hydroxy acid salicylate for initiation of salicylate-capped siderophores have 
been the focus of much work. These include siderophores from Y. pestis and Y. 
enterocolitica (causative agent of yersinosis, a diarrheal disease; siderophore: yersiniabactin, 
Figure 2A), M. tuberculosis (mycobactin, Figure 2B), and P. aeruginosa (pyochelin, Figure 
3A).
The most advanced study is related to the inhibitor called salicyl-AMS for 5′-O-(N-
salicylsulfamoyl)adenosine (Figure 5A). This nonhydrolyzable reaction intermediate was 
shown to have low nanomolar IC50 values for the salicylate adenylation enzymes MbtA (M. 
tuberculosis), YbtE (Y. pestis), and PchD (P. aeruginosa), and to have low micromolar EC50 
values for growth inhibition of M. tuberculosis and Y. pestis [36]. Salicyl-AMS is sometimes 
also called a bisubstrate inhibitor (as opposed to a reaction intermediate), because it links the 
salicylate ring to the sugar nucleotide. Using primarily MbtA as the model enzyme and M. 
tuberculosis as the organism, there have been many variations on the salicyl-AMS theme: i) 
exchanging the acylsulfamate linkage with a β-ketosulfonamide linkage (green in Figure 
5A) [37]; ii) differing glycosyl modifications (yellow) [38]; iii) modification at the salicyl 
ring position (blue) [39]; iv) decorations to the salicyl ring in combination with salicyl-sugar 
linkages (blue and green) [40]; v) modification of the nucleobase (orange) [41]; and vi) 
triazole derivatives of the nucleobase (orange) [39]. These extensive structure-activity 
studies yielded compounds of comparable or worse values for enzyme inhibition and 
bacterial growth inhibition when compared to the parent compound. Salicyl-AMS has 
subsequently been shown to be effective in significantly inhibiting M. tuberculosis growth in 
a mouse model; however, the compound was toxic to the mice at the higher dose (~17 mg/
kg), which was proposed to be the result of off-target effects [42].
4.2.2 Dihydroxybenzolate adenylation inhibitors—Inhibitors have also been 
designed to the dihydroxybenzoate-adenylating enzymes. Dihydroxybenzoate (DHB) 
capped siderophores are generated by E. coli (enterobactin), V. cholera (vibriobactin), and 
B. subtilis (bacillibactin) (Figure 6). Early work included the design of a variety of AMS 
derivatives with differing decorations on the benzoyl ring, and also to hydroxamoyl 
adenosine (AMN) derivatives (Figure 5B), yielding nanomolar inhibition constants when 
tested against both the dihydroxybenzoate-adenylating enzyme from B. subtilis (DhbE) and 
the salicylate-adenylating enzyme from Y. pestis (YbtE) [43]. Nanomolar inhibition was 
reported for 2,3-dihydroxybenzohydroxamoyl adenylate when tested against the 
dihydroxybenzoate-adenylating enzyme from E. coli (EntE) (Figure 5C) [44]. Inhibition of 
EntE by salicyl-AMS and dihydroxybenzoate-AMS were reported to be of a one-step, slow-
onset, tight-binding mechanism, again with low nanomolar inhibition [45].
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The dihydroxybenzoate-adenylating enzyme from Acinetobacter baumannii (a nosocomial, 
opportunistic pathogen) provides the DHB cap for the siderophore acinetobactin (Figure 6). 
A fluorescence polarization based high throughput screen was developed for BasE, in which 
a probe was generated that consisted of a fluorescein attached to the 2′-O of the ribosyl 
moiety of salicyl-AMS thru a linker [46]. Displacement of the probe from the enzyme active 
site by an inhibitor leads to increased fluorescence depolarization. A screen of ~84,000 
compounds produced several inhibitor chemotypes that were effective not only against 
BasE, but also against the DHB adenylation domains EntE (E. coli), VibE (V. cholera), 
DhbE (B. subtilis), and the salicylate adenylation enzymes MbtA (M. tuberculosis) and YbtE 
(Y. pestis). The most promising compound contains a pyrazolo[5,4-a]pyridine scaffold (KD 
of 78 nM) is shown in Figure 5D. Since that time, the structure of BasE has been determined 
in three states: a) with the compound from the screen bound (magenta in Figures 5E and 5F), 
b) with DHB-AMS bound (green), and c) with a triazole derivative of DHB-AMS bound 
(cyan)[47]. The bisubstrate inhibitors bound as predicted by a previous MbtA homology 
model derived from the DhbE structure, driven by product (adenylated-DHB) binding 
modes found in DhbE [41]. Binding in the active site of the pyrazolo[5,4-a]pyridine was 
expected because of the documented competitive inhibition; however, the new chemotype 
did not bind as predicted by docking algorithms. The phenyl ring of pyrazolopyridine-
inhibitor was anticipated to align with the DHB ring of the AMS-inhibitor structures, 
whereas the pyridine ring (pyrazolopyridine-inhibitor) was predicted to align with the 
adenine (AMS-inhibitor) [46]. Instead, the crystal structure shows a unique pose: note the 
change in the orientation of the pyraxolopyridine ring system in magenta in Figure 5F [47].
4.2.3 Macrocyclic inhibitors of cysteine adenylation—The AMS inhibitors have not 
been expanded to amino acid substrates because aminoacyl-tRNA synthetases perform very 
similar chemistry. Therefore, aminoacyl-AMP analogues, such as aminoacyl-AMS, will 
inhibit both ribosomal protein formation [48] and NRPS synthesis of natural products. 
Indeed, [(phenlylalanine)sulfamoyl] adenosine inhibits the phenylalanine adenylation 
domain (PheA) in gramicidin biosynthesis (Bacillus brevis) and [(leucine)sulfamoyl] 
adenosine inhibits the leucine adenylation domain (LeuA) in surfactin biosynthesis (B. 
subtilis) with nanomolar Ki values4, and both also inhibit tRNA synthetases [49]. Tan and 
colleagues [50] very cleverly generated cysteine- and alanine-AMS, and also macrocyclic 
alanine-AMS where the alanine sidechain is linked back to the nucleobase by 2 or 3 carbon 
units (Figure 7A). They first showed that the cysteine- and alanine-AMS inhibited both the 
adenylation domain of HMWP2 (High Molecular Weight Protein 2 – a two module NRPS in 
the biosynthesis of yersiniabactin) and inhibited in vitro translation. Next, they showed that 
the macrocyclic alanine-AMS inhibited HMWP2 adenylation activity but not in vitro 
translation.
4.2.4 Vinylsulfonamide inhibitors for trapping adenylation-carrier domain 
interaction—It should be noted that adenylation domains of NRPS domains are 
remarkably mobile, having distinct conformations for the activation of the amino or hydroxy 
acid followed by a large conformational change to attach the amino/hydroxy acid to the 
4A Ki value reports the equilibrium dissociation constant of the inhibitor.
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carrier domain on the pantetheine group [51–54]. This flexibility can make adenylation 
domains problematic in crystallographic studies. Vinylsulfonamide inhibitors are 
mechanism based inhibitors that covalently attach the carrier domain panthetheine group to 
a dead end analogue of the AMS compounds (Figure 7B). The vinylsylfonamide inhibitors 
have been used to lock an adenylation domain in a closed conformation in a valine specific 
adenylation-carrier protein didomain from P. aeruginosa called PA1221 [55] (Figure 7C and 
7D) and similarly for an EntE (adenylation)- EntB (carrier domain) artificial construct [53]. 
EntE, a stand alone adenylation domain, was cloned so that the resulting peptide was linked 
by a four amino acid linker to the carrier domain of EntB. While the vinylsufonamide 
compounds may be unlikely drug leads, they are excellent chemical biology probes for 
understanding protein-protein or domain-domain interfaces in these complex multi-domain, 
multi-protein molecular machines.
4.3. An NRPS enzyme as inhibitor
Chillar and colleagues [56] tested whether microbial competition could be exploited to find 
new antifungal proteins. Cell free extracts containing secretory proteins or cytoplasmic 
proteins were tested for antifungal properties against A. fumigatus, A. flavus (causes 
aspergillosis in immunocompromised patients) and A. niger (a food contaminant, causes 
black mold on fruits and vegetables). A protein from E. coli was identified that inhibited 
fungal growth. While the tests were not conducted under conditions of iron limitation, the 
protein was identified as an NRPS in a siderophore biosynthetic cluster, and the protein was 
subsequently shown to inhibit siderophore production by A. fumigatus.
5. Inhibitors of PKS biosynthesis
Inhibition of PKS biosynthesis is a difficult target for drug design because of the similar 
chemistry, logic and structure shared with the enzymes of fatty acid biosynthesis. Indeed, 
PKS and fatty acid synthase (FAS) enzymes have been hypothesized to have evolved from a 
common ancestor [14]. As described above for PKS biosynthesis, FAS tether initiation and 
elongation units (malonyl or methylmalonyl CoA) to carrier domains for condensation by 
ketosynthase domains [14, 57]. To generate the fully unsaturated hydrocarbon of a fatty 
acid, each module contains ketoreductase, dehydratase, and enoylreductase domains. As 
mentioned previously, PKS modules may have some, all, or none of these tailoring domains 
to generate more varied natural products. Therefore, inhibitors of pathogenic PKS enzymes 
will likely also be inhibitors of host FAS enzymes, making design of selective inhibitors for 
the complex and quite large PKS enzymes problematic. Instead, PKS drug design has 
focused on identifying and developing novel polyketides with therapeutic properties [58, 
59].
6. Inhibitors of NIS biosynthesis
S. aureus, including MRSA, and Bacillus anthracis (causative agent of anthrax) make 
siderophores using a nonribosomal peptide synthetase independent pathway, with the 
production of staphyloferrin B and petrobactin (respective siderophores) being strongly 
linked to survival in iron limiting conditions. The NIS synthetases, SbnE for S. aureus and 
AsbA for B. anthracis, link citric acid to an amine alcohol (former) or a polyamine (latter) 
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(Figures 8A and 8B). This process is ATP dependent, adenylating the citrate with 
elimination of pyrophosphate before linking to the citrate to the amine, with loss of AMP, 
reminiscent of the chemistry performed by NRPS adenylation domains but without the 
thiotemplate assembly line. An activity assay was developed for high throughput screening 
(originally intended for NRPS enzymes) that converts the pyrophosphate to inorganic 
phosphate which is detected by malachite green [60]. A screen was designed to only identify 
compounds from a marine microbial-derived natural product library that inhibited both SbnE 
and AsbA [61]. The result was the identification of the baulamycins (Figure 8C) as 
competitive, reversible inhibitors with IC50 values in the micromolar range. The 
baulamycins, however, inhibit growth of the pathogens in both iron-replete and iron-limiting 
media, indicating the compounds are nonspecific.
7. Generation of secondary metabolites for incorporation into siderophores
Frequently, siderophores include building blocks such as modified amino acids or hydroxy 
acids that must be produced for incorporation into the backbone. Some building blocks are 
modified by tailoring domains that are incorporated into the NRPS or PKS modules or 
alternatively found as stand-alone domains that interact with an NRPS module. In other 
cases, there are enzymes in the biosynthetic cluster that generate the building blocks in 
advance of their use by the synth(et)ases. Several of these accessory enzymes have been the 
targets of rational and high throughput drug design. In particular, these include enzymes that 
generate isochorismate, salicylate, and hydroxyornithine.
7.1. Isochorismate synthase and salicylate synthase
The enzymes that produce isochorismate and salicylate for the production of salicylate- and 
dihydroxybenzoate-capped siderophores are all structural homologues of the Menaquinoe, 
Siderophore, Tryptophan (MST) class. Chorismate is the substrate for these enzymes, 
thereby also earning the name “chorismate-utilizing” enzymes, and is at the branchpoint of 
the shikimate pathway for the production of aromatic amino acids by bacteria, fungi and 
plants, but this pathway is not found in animals. The MST enzymes are magnesium 
dependent and all perform the isomerization of the chorismate ring to form isochorismate by 
general acid-general base chemistry [62–64]. Some of the enzymes are capable of only this 
chemistry, and are thus called isochorismate synthases. In contrast, the salicylate synthases 
then cleave the pyruvylenol tail from the ring to generate salicylate and pyruvate (Figure 
9A). Both reactions occur in the same active site. The cleavage reaction has been 
hypothesized to be a pericyclic reaction [64, 65]; however, there is a recent resurgence for 
the idea that the elimination reaction is also general acid-general base catalyzed [66].
The isochorismate synthase from E. coli (EntC for the production of enterobactin), and 
salicylate synthases from Y. enterocolita (Irp9, yersiniabactin) and M. tuberculosis (MbtI, 
mycobactin) have been the subject of many rational inhibitor design initiatives. Frequently, 
the investigators tested their compounds on several enzymes simultaneously, and sometimes 
in conjunction with structurally and functionally related chorismate-utilizing enzymes that 
generate anthranilate for tryptophan biosynthesis and 4-amino-4-deoxychorismate for folate 
biosynthesis. The earliest investigations were based on a mechanism described for EntC in 
which the hydroxyl groups of the isomerization are both chelated by magnesium ion at the 
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transition state [67], yielding the rationally designed inhibitors such as the one shown in 
Figure 9B [68, 69]. The racemic compounds were strong competitive inhibitors with a high 
nanomolar Ki value.
The first structures for the MST enzymes (anthranilate synthase [70–72] and 4-amino-4-
deoxychorismate synthase [73]) were solved showing that the magnesium does not bind the 
chorismate substrate through the hydroxyls, but rather through the ring carboxylate, leading 
to the hypothesis of acid-base chemistry. With this information in hand, a larger array of 
chorismate and isochorismate analogues were made and tested, including: i) variations at the 
hydroxyl sites [74]; ii) variations at the pyruvylenol tail [74–77], and iii) use of benzoate, 
pyridine and pyridone rings [75, 76, 78]. These compounds were tested against Irp9, MbtI, 
and/or EntC with the best compounds, with modifications to the terminal alkene of the 
pyruvylenol tail, exhibiting low micromolar inhibition (Ki values). The benzoate analogues 
were predicted by docking experiments to bind in a pose similar to chorismate which the 
ring carboxylate bound to the magnesium for the salicylate adenylation enzymes [75, 78], 
but in a flipped pose where the ring carboxylate bound in the site usually occupied by the 
pyruvyl-carboxylate for isochorismate synthase EntC (the change in pose is based on the 
enzyme) [78]. When the crystal structures of the salicylate synthase MbtI were determined, 
the benzoate compound bound in the chorismate-like pose, but inhibitors with additions to 
the pyruvylenol tail bound flipped (the change in pose is based on inhibitor) [79]. Figures 9E 
and 9F show the product-bound structure of Irp9 (salicylate and pyruvate in purple) [80] 
overlayed with the benzoate inhibitor structure (yellow, same pose as products) [79], and the 
benzoate inhibitor with a methylated pyruvylenol tail (cyan, flipped pose) in MbtI.
In another rational design effort, an elaborate construct was generated in which a chorismate 
mimic (“payload”) was connected by a “spacer” to a “combi” section intended to extend out 
of the active site and interact with the surface of the protein. These constructs yielded 
compounds that are millimolar to high micromolar EntC inhibitors [81]. Finally, inhibitors 
of MbtI were sought through a high throughput screen that exploits the fluorescent nature of 
the product salicylate [82]. Sixteen compounds from the screen were confirmed with an 
orthogonal assay and two of these compounds, a diarylsulfone and a benzimidazole-2-
thione, were considered good leads and structure activity relationships were determined. The 
diarylsulfone is a pan assay interference compound [83] and an unlikely candidate; however, 
a benzimidazole-2-thione exhibits low micromolar inhibition and is shown in Figure 9C.
7.2 Isochorismate pyruvate lyase
P. aeruginosa generates a salicylate-capped siderophore, but the MST enzyme in the 
siderophore biosynthetic pathway for pyochelin (Figure 3A) is an isochorismate synthase 
(PchA, Figure 9A, blue) that is incapable of the lyase reaction [84]. A second enzyme in the 
pathway, PchB, is an isochorismate-pyruvate lyase performing the pericyclic elimination 
reaction (Figure 9A, green) [85]. A high throughput screen was designed that exploits 
salicylate fluorescence, and the hits were tested for inhibition in PchB, the Y. enterocolitica 
salicylate synthase Irp9 (Section 7.1) and also E. coli chorismate mutase (EcCM) [86]. The 
rationale was that Irp9 performs the same reaction, and EcCM is a structural homologue 
performing a similar reaction with a similar transition state. Mid nanomolar PchB inhibitors 
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(IC50 values) were identified. Two demonstrated growth inhibition of P. aeruginosa in the 
millimolar range (EC50 values) in iron-poor media, but were ineffective in iron-replete 
media, as would be expected for an inhibitor specific for siderophore biosynthesis. One of 
the compounds was also a nanomolar inhibitor of Irp9 and a micromolar inhibitor of EcCM 
(IC50 values) that demonstrated growth inhibition for Y. enterocolitica and E. coli in the 
millimolar range (EC50 values). This most successful compound is shown in Figure 9D. The 
similarity of this scaffold to that in Figure 9C, which was found in a high throughput screen 
for MbtI (Section 7.1), should be noted.
6.3. Ornithine hydroxylase
Hydroxamate siderophores are constructed by NRPS enzymes using modified lysine, 
ornithine, or polyamines such as spermine. The first step is the hydroxylation of the 
sidechain amine followed by formylation of the same nitrogen to make the hydroxamate 
moiety that chelates the iron in the fully formed siderophore. Examples include the formyl-
hydroxyornithine residues of pyoverdin (blue in Figure 3B) and the hydroxylysine residues, 
one acylated and one cyclized, in mycobactin (blue in Figure 2B). The hydroxylation 
reaction is carried out by an N-hydroxylating flavin monooxygenase, and has been the target 
for the development of a fluorescence polarization screen [87]. The goal was to make a 
probe that would bind in the NADPH binding site linked to a fluorophore (rhodamine or 
TAMRA) (Figure 10B). The result was a compound that served as a competitive inhibitor to 
NADPH (as designed) and also ornithine, suggesting that the fluorophore bound across the 
substrate binding site. The assays were conducted against SidA, the ornithine hydroxylase of 
A. fumigatus required for the production of the siderophores ferricrocin and ferrichrome 
(Figure 10A), and also the lysine hydroxylase from the non-pathogenic Mycobacterium 
smegmatis (MbsG) for the production of the mycobactin siderophores. A very limited initial 
screen (160 compounds) identified sanguinarine (Figure 4D) has a weak inhibitor of SidA 
(high micromolar IC50 value). The fluorescence polarization probe for these experiments 
(Figure 10B) is very similar to the probes designed for the Sfp-PPTase experiments (Figures 
4A and 4C), differing only in the linker between the sugar-nucleotide and the fluorophore. 
Screens for Sfp and SidA identified the same compound, sanguinarine, as an inhibitor, 
despite the assayed enzymes being structurally and functionally unrelated. It may be 
important to determine if the sanguinarine is primarily interrupting an interaction of the 
fluorophore with the enzymes in each case, instead of inhibiting binding of the portion of the 
probe designed to mimic substrate. Additionally, sanguinarine has been shown to be thiol-
reactive [88] and has been reported as an inhibitor of many diverse targets (some examples 
[89–98]).
7.4. Ornithine decarboxylase
Putrebactin, a macrocyclic dihydroxamate siderophore, is generated by Shewanella 
putrefaciens (a marine bacteria that rarely causes bacteremia) using NIS synthetases from 
precursors putrescine and succinate (Figure 11A). Putrescine is generated from ornithine by 
the enzyme ornithine decarboxylase. Unnatural siderophores can be generated by S. 
putrefaciens when an ornithine decarboxylase inhibitor is added to the culture. In particular, 
desferrioxamine B, a cadaverine-substituted form of putrebactin, was generated with the 
addition of the inhibitor 1,4-diamino-2-butanone (Figure 11B) [99]. Further, an unsaturated 
Lamb Page 12













macrocycle was made in the presence of the inhibitor co-administered with the putrescine 
analogue 1,4-diamino-2-butene (Figure 11C) [100].
8. Siderophore maturation
Some siderophores require maturation after the synthesis of the backbone is complete. 
Pyoverdin from P. aeruginosa (Figure 3B), is one such siderophore: the peptide backbone is 
synthesized by NRPS enzymes in the cytoplasm, and maturation of the fluorescent 
chromophore occurs in the periplasm before export [101]. PvdQ is one of the maturation 
enzymes, acting as an NTN hydrolase [102] to cleave off the fatty acid myristate 
incorporated by the first module of the first NRPS (PvdL) [103]. PvdQ also has a role in 
quorum-quenching by degrading long-chain N-acylhomoserine lactones, which are major 
communication molecules of Gram-negative bacteria, and their destruction causes a 
decrease in the expression of virulence factors and a decreased ability to form biofilms 
[104]. In this latter capacity, an inhalable preparation of freeze-dried PvdQ powder has been 
prepared as a potential treatment for cystic fibrosis patients where P. aeruginosa causes 
chronic infections [105].
A high throughput screen was developed against PvdQ hydrolase activity for the maturation 
of pyoverdin [103, 106]. Two reporter probes were identified: the colorimetric 4-nitrophenyl 
myristate and the fluorescent 4-methyl-umbelliferyl laurate (Figure 12A), which served as 
substrates in the screen. An initial screen of 1280 compounds produced two compounds with 
micromolar IC50 values [103]. The inhibitors were shown by crystallography to have 
overlapping binding sites with myristate. A subsequent screen of more than 300,000 
compounds using the 4-methyl-umbelliferyl laurate substrate yielded a 40 nM inhibitor 
(IC50 value) which was subsequently refined by structure activity relationship analysis to 
produce a 20 nM inhibitor called ML318 (Figure 12B) [106, 107]. ML318 inhibited the 
production of pyoverdin and inhibited P. aeruginosa growth under iron-limiting conditions 
with an EC50 value less than 50 μM [106]. Furthermore, ML318 showed no apparent 
toxicity in HeLa cells at the same concentration. The crystal structure shows ML318 binding 
in the acyl-binding site (Figures 12D and 12E) [107]. A combination treatment of ML318 
with flucytosine (Figure 3C) yielded a complementary effect, with an EC50 value of ~2 μM. 
A rationally designed boronic acid inhibitor demonstrated a picomolar Ki value (Figure 12C) 
[108]. This transition state analogue binds covalently to the active site serine nucleophile 
(shown crystallographically, Figure 12D and 12E), and inhibits P. aeruginosa growth under 
iron-limiting conditions when co-administered with an efflux pump inhibitor. A series of n-
alkylboronic acid compounds were tested kinetically and structures determined, with the 
C12- and C13-B(OH)2 compounds remaining the most potent [109].
8. Conclusions
The focus of research for inhibiting siderophore biosynthesis has been directed at a variety 
of accessory enzymes that generate secondary metabolites for incorporation into 
siderophores, production of the phosphopantethienyl posttranslational modification of 
carrier domains, incorporation of hydroxy acids by NRPS enzymes, and a siderophore 
maturation fatty acid hydrolase enzyme. Targeting the NRPS synthetase, PKS synthase and 
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NIS synthetase enzymes has the confounding problem of selectivity with the need to avoid 
inhibiting either aminoacyl-tRNA synthetases or fatty acid synthases. The macrocyclic 
inhibitor effective against the cysteine adenylation domains but selective so as not to inhibit 
the aminoacyl-tRNA synthetases demonstrates that even this difficult problem is not out of 
reach [50]. An avenue not yet exploited is inhibition of tailoring activities, those domains 
that modify peptide or ketide units while still attached to the assembly line enzymes.
Finding potent and selective inhibitors of siderophore biosynthetic enzymes is just one 
requirement for developing a successful antibiotic treatment. Many bacteria have redundant 
iron-scavenging systems, including the use of more than one siderophore and/or heme 
uptake. Some express multi-drug efflux pumps, contain porin variants, or exist in biofilms 
that might impact the ability of inhibitors to reach their targets. The most successful projects 
have produced pico- and nanomolar inhibitors that show iron-dependent growth inhibition of 
the targeted pathogen when the pathogen is grown in culture. Testing in animal models, like 
that highlighted herein for the salicyl-AMS inhibitor [42], is the next necessary step for most 
of these translational projects [110].
Biosynthesis is but one target when considering how to develop antimicrobials directed at or 
exploiting siderophore-dependent iron nutritional immunity. Considerable effort has been 
expended in tricking siderophore uptake systems to import antibiotics, the Trojan horse 
strategy [111, 112]. Interestingly, nature (in the form of Streptomyces) was the first designer 
of Trojan Horse antibiotics, linking the siderophore ferrichrome to a peptidylnucleoside 
antibiotic to generate albomycins [113]. Conversely, blocking siderophore export yields a 
toxic cytoplasmic buildup of siderophores [114]. Development of natural products with 
novel bioactive properties by engineering PKS and NRPS assembly lines has long been a 
goal of metabolic engineers with significant recent advances (some examples are found in 
references [115–120]). Regardless of how the systems for siderophore iron-scavenging are 
exploited, iron scavenging pathways provide a key access point for fighting the looming 
health crisis of antibiotic resistance in pathogenic microbes. The collected work of this 
review shows the promise and recent successes for targeting inhibitors at the biosynthesis of 
siderophores in the design of new antimicrobial therapies.
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Figure 1. Siderophore biosynthesis
A. Nonribosomal peptide synthetase chain elongation. The adenylation domain activates an 
amino acid and attaches it to the carrier domain, thereby priming the module (top line). The 
condensation domain forms a peptide bond between two primed modules (bottom line). The 
process continues with more modules in an assembly line fashion. A = adenylation, C = 
condensation, PCP = peptidyl carrier protein. The wavy line in the PCP domain denotes the 
phosphopantethienyl post-translational modification. B. Polyketide synthase bond 
formation. The acyl transferase domains load acyl groups onto the carrier domains of the 
loading module and module 1 (top). The acyl group from the loading module is transferred 
to the ketosynthase domain of module 1 thereby priming the module (bottom left). The 
ketosynthase domain performs the condensation reaction (bottom right). The growing chain 
is transferred to the ketosynthase domain of the next module for the assembly line to 
continue. AT = acyl transferase, ACP = acyl carrier protein, KS = ketosynthase. The wavy 
line in the ACP domain denotes the phosphopantethienyl post-translational modification. 
The short, straight line in the KS domain denotes an active site cysteine. C. Post 
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translational modification of carrier domains to generate phosphopantetheinyl swinging arm. 
CP = carrier protein is striped in shades of green to represent that this is common to both 
NRPS (dark green) and PKS (light green) carrier domains. SFP is a promiscuous PPTase 
from Bacillus subtilis commonly used to perform this reaction in vitro.
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Figure 2. Siderophore mimics
Salicylate-capped siderophores yersiniabactin (A) and mycobactin (B). The salicylate caps 
are shown as red. Hydroxylysine residues are blue. C. Scaffold for siderophore mimics with 
antimicrobial activity against Y. pestis and M. tuberculosis [20]. D. Spiro-indoline-
thiadiazole inhibitor that converts to a merocyanine metal chelator and has antimicrobial 
activity against E. coli [21].
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Figure 3. Repurposing drugs
The P. aeruginosa siderophores pyochelin (A) and pyoverdin (B). In pyochelin, the 
salicylate cap is again red. In pyoverdin, the formyl-hydroxyornithine residues are blue. C. 
Flucytosine.
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Figure 4. Phosphopantetheinyl transferase probes and inhibitor
A. The FRET probes developed to determine inhibitors of PPTase enzymes. [28] The serine 
where the PPTase attaches the FRET acceptor to the FRET donor-labeled peptide is shown 
in red. B. ML267 inhibitor of Sfp-PPTase identified by high throughput screening using the 
FRET assay using probes in part A. [31, 32] C. BODIPY-TMR fluorescence polarization 
probe developed to assay PPTase inhibitors. [33] D. The two most inhibitory compounds of 
the PPTase from M. tuberculosis are shown, determined when using the fluorescence 
polarization assay where the probe is the FRET acceptor in part A. [34, 35]
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Figure 5. Inhibitors of salicylate and dihydroxybenzoate adenylation enzymes
A. Salicyl-AMS, a rationally designed reaction intermediate analogue. [36]. B. Benzoyl-
AMN [43]. C. DHB-hydroxamoyl adenylate [44]. D. Inhibitor from high throughput screen. 
[46]. E. Three structures of BasE are overlayed: BasE with DHB-AMS bound is the orange 
cartoon with green stick inhibitor (PDB ID: 3O82), with a triazole derivative of DHB-AMS 
shown in cyan sticks (PDB ID: 3O83), and with inhibitor from part D shown in magenta 
sticks (PDB ID: 3O84). F. The area in the box in part E is shown in stereo (all stereo images 
are wall-eye or divergent stereo). Note the unexpected binding mode of the magenta HTS 
inhibitor relative the green and cyan substrate analogue inhibitors. Structure figures made in 
PyMOL [121].
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Figure 6. Dihydroxbenzoate-capped siderophores
Bacillobactin from B. subtilis, acinetobactin from A. baumannii, enterobactin from E. coli, 
and vibrobactin from V. cholera. DHB caps are shown in pink.
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Figure 7. Inhibitors of adenylation domains in NRPS modules
A. Macrocyclic inhibitor of cysteine adenylation domain in HWMP2 for yersiniabactin 
biosynthesis. [50] B. Mechanism based inhibitor used to trap adenylation and carrier 
domains in stable conformation. The one shown here was designed for the DHB-specific 
EntE [53]. C. The structure of the carrier domain (green cartoon) and adenylation domain 
(orange) with the vinylsulfonamide inhibitor (magenta sticks) of PA1221 from P. 
aeruginosa, a two domain NRPS specific for the incorporation of valine (PDB ID: 4DG9). 
D. Close up of the active site showing the covalent linkage of the adenylation domain 
inhibitor (similar to that in part B) to the phosphopantetheinyl post translation modification 
of the carrier domain.
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Figure 8. NRPS-independent siderophore (NIS) synthetase inhibitor
A. Condensation of citric acid (blue) with diaminopropionic acid (red) by NIS synthetase 
SbnE from S. aureus for the production of staphyloferrin. B. Condensation of citric acid 
(blue) with spermidine (green) by NIS synthetase AsbA from B. anthrasis for the production 
of petrobactin. C. Micromolar antibiotic inhibitor of SbnE and AsbA [61].
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Figure 9. Isochorismate synthase, salicylate synthase, isochorismate-pyruvate lyase
A. Salicylate production for the generation of salicylate-capped siderophores. B. Potential 
transition state analogue inhibitor for isochorismate synthase activity. [68] C. Salicylate 
synthase inhibitor from HTS. [82] D. Isochorismate-pyruvate lyase inhibitor from HTS that 
also is effective against salicylate synthase and chorismate mutase. [86]. E. The structure of 
the salicylate synthase from Y. enterocolitica (Irp9, purple cartoon, PDB ID: 2FN1) with the 
catalytic Mg ion (green sphere) and products salicylate and pyruvate (purples sticks) was 
used to align two inhibitor-bound structures of the salicylate synthase from M. tuberculosis, 
MbtI. An MbtI structure with the required Mg has never been determined. The structure of 
MbtI with the aromatized isochorismate analogue known as AMT is shown in yellow sticks 
(PDB ID: 3ST6). MbtI with methyl-AMT is shown in cyan sticks (PDB ID: 3VEH). The 
methyl group addition is at the –ene of the pyruvylenol tail. Cartoons for 3ST6 and 3VEH 
are not included for the sake clarity. F. Close up of the active site is shown in stereo 
illustrating the binding modes of the inhibitors relative to products. Note that AMT (yellow) 
binds similarly to the substrate/products, with the salicyl ring analogue coordinated to the 
Mg2+. By contrast, additions to the pyruvylenol tail cause a flipping of the binding mode 
(methyl-AMT as one example, cyan) with the salicyl ring analogue now binding in the 
location where the pyruvate product is normally found.
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Figure 10. Ornithine hydroxylase
A. Ferrichrome and ferricrocin siderophores from A. fumigatus. The formyl-
hydroxyornithine residues are blue. B. ADP-TAMRA chromophore designed for a high 
throughput assay for the flavin-dependent N-hydroxylating monooxygenases, such as 
ornithine and lysine hydroxylases.
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Figure 11. Inhibiting ornithine decarboxylase to generate novel siderophores
A. Putrebactin, the natural siderophore of S. putrefaciens with putrescine (diaminobutane, 
red) incorporated. B. When ornithine decarboxylase is inhibited, preventing the production 
of putrescine, then S. putrefaciens makes desferrioxamine, using cadaverine 
(diaminopentane, green) instead. C. When ornithine decarboxylase is inhibited and an 
external source of diaminobutene (blue) is added to the culture, then an unsaturated form of 
putrebactin is formed.
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Figure 12. Reporter substrates and inhibitors for PvdQ
A. Substrate analogue probes. 4-nitrophenyl myristate provides an absorbance readout, 
whereas 4-methyl-umbelliferyl laurate is fluorescent when cleaved. [103] B. Inhibitor of 
PvdQ identified by high throughput screening and SAR. [106, 107] C. Rationally designed 
transition state analogue inhibitor [108]. D. The PvdQ structures with ML318 (PDB ID: 
4K2G, inhibitor in green sticks) and tridecylboronic acid (PDB ID: 4M1J, inhibitor cyan) 
are overlayed. Only the latter cartoon is shown for clarity. E. Stereoview of active site with 
inhibitors bound. Note that the boronic acid inhibitor (boron is pink) forms a covalent 
transition state analogue with the serine nucleophile (grey sticks).
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